title: Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients.
abstract: Between September 1994 and October 1995, we diagnosed and treated four cases of early onset posttransplantation lymphoproliferative disorder (PTLD) occurring within 62 days of pancreas transplantation. The development of PTLD was associated with both a significantly higher total muromonab-CD3 (OKT3) dose and a lack of ganciclovir/acyclovir prophylaxis, but it was not associated with the total dose of antithymocyte globulin or cytomegalovirus serostatus. All four patients were treated aggressively and survived without evidence of recurrent PTLD more than 1.5 years later. We conclude that the use of a high total dose of OKT3 puts pancreas transplant recipients at increased risk for early onset PTLD, while ganciclovir/acyclovir prophylaxis may help to prevent this disorder; however, if early onset PTLD does occur in these patients, aggressive therapy can lead to a favorable outcome.
authors.affiliation: Department of Medicine (Divisions of Infectious Diseases and Nephrology), University of Maryland School of Medicine, Baltimore, USA.
authors.forename: S
authors.initials: S
authors.lastname: Keay
authors.forename: D
authors.initials: D
authors.lastname: Oldach
authors.forename: A
authors.initials: A
authors.lastname: Wiland
authors.forename: D
authors.initials: D
authors.lastname: Klassen
authors.forename: E
authors.initials: E
authors.lastname: Schweitzer
authors.forename: L V
authors.initials: LV
authors.lastname: Abruzzo
authors.forename: D
authors.initials: D
authors.lastname: Kumar
authors.forename: S
authors.initials: S
authors.lastname: Bartlett
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D015774:Ganciclovir; D000212:Acyclovir